Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 3/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7433358 | 0.87 | CPA1 (0.53) | MMEANPEP | |
| SCHEMBL7320338 | 0.82 | MMP12 (0.44) | LTB4RLTB4R2 | |
| SCHEMBL7322599 | 0.81 | MMP1 (0.39) | KMT2A | |
| SCHEMBL7322606 | 0.80 | CTSS (0.40) | — | |
| SCHEMBL5709642 | 0.80 | MMP1 (0.38) | — | |
| SCHEMBL7436937 | 0.80 | MME (0.41) | MMELAP3TDP1ANPEP | |
| SCHEMBL6349082 | 0.79 | KDM4E (0.39) | KMT2ALAP3ANPEP | |
| SCHEMBL5709644 | 0.78 | CTSS (0.35) | — | |
| SCHEMBL7290455 | 0.78 | CPA1 (0.46) | MMEANPEP | |
| SCHEMBL7399070 | 0.78 | CPA1 (0.46) | MMEANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | claimed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | claimed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | claimed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | claimed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-5229420-A | Renin inhibitor | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| WO-1990000051-A1 | ETHEREAL N-TERMINAL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| EP-0349921-A2 | Etheral n-terminal aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | LTB4R 1702/4885LTB4R2 1542/4885MME 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.